Table 2 Cardiovascular outcome trials completed in 2020: comparison of active vs. placebo group
From: Report from the CVOT Summit 2020: new cardiovascular and renal outcomes
VERTIS-CV [23] | SCORED [28] | ||
|---|---|---|---|
Class & cardiovascular outcomes | HR (95.6% CI) p-value | Class & cardiovascular outcomes | HR (95.6% CI) p-value |
Primary composite outcome Composite outcome of MACE (CV death, nonfatal MI, nonfatal stroke) | 0.97 (0.85–1.11) p < 0.001 | Primary composite outcome Total occurrences of CV death, HHF, and urgent visits for HF | 0.74 (0.63–0.88) p < 0.001 |
Secondary outcome CV death or HHF | 0.88 (0.75–1.03) p = 0.11 | Secondary outcome Total occurrence of HF events | 0.67 (0.55–0.82) p < 0.001 |
Secondary outcome CV death | 0.92 (0.77–1.11) p = 0.39 | Secondary outcome CV death | 0.90 (0.73–1.12) p = 0.35 |
Secondary outcome Hospitalization for heart failure | 0.70 (0.54–0.90) p = 0.006 | Secondary outcome 3P-Mace and HHF events | 0.72 (0.63–0.83) |
Secondary outcome Kidney composite: dialysis/transplant, doubling of serum creatinine level, or renal death | 0.81 (0.63–1.04) p = 0.08 | Secondary outcome All-cause mortality | 0.99 (0.83–1.18) |
Adverse events | Event rate (%) active vs. placebo group | Adverse events | Event rate (%) active vs. placebo group |
|---|---|---|---|
Urinary tract infection | 12.2 vs. 12.0 vs. 10.2 | Diarrhea | 8.5 vs. 6.0 |
Acute pancreatitis | 0.4 vs. 0.2 vs. 0.4 | Genital infections | 2.4 vs. 0.9 |
Diabetic ketoacidosis | 0.3 vs. 0.4 vs. 0.1 | Diabetic ketoacidosis | 0.6 vs. 0.3 |